Browse > Article
http://dx.doi.org/10.5012/jkcs.2010.54.01.077

Synthesis and 3D-QSAR of p-Hydroxybenzohydrazide Derivatives With Antimicrobial Activity Against Multidrug-Resistant Staphylococcus aureus  

Bhole, Ritesh P. (Department of Pharmaceutical Chemistry and Drug Discovery Sharad Pawar College of Pharmacy)
Bhusari, Kishore P. (Department of Pharmaceutical Chemistry and Drug Discovery Sharad Pawar College of Pharmacy)
Publication Information
Abstract
Hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) has been an increasing problem worldwide since the initial reports over 40 years ago. To examine new drug leads with potential antibacterial activities, Various N'-[(-3-substituted-4-oxo-1,3-thiazolidin-2-ylidene]-4-hydroxy benzohydrazide (4a-4.i) and N'-[-(3,4-disubstituted)-1,3-thiazolidin-2ylidene)]-4-hydroxybenzohydrazide from (5.a-5.i) to (10.a-10.i) were synthesized using appropriate synthetic route. The entire test compounds (4.a-4.i) and from (5.a-5.i) to (10.a-10.i) were assayed in vitro against s. aureus strain. The minimum inhibitory concentration (MIC) was determined for test compounds and for reference standards. The test compounds showed significant antibacterial activity against the strains used, when tested in vitro. In general, p-hydroxybenzohydrazide ring and substituted thiazoline ring are essential for antimicrobial activity. Among the compounds tested, compounds 6.f, 7.g, 9.f and 10.f, 10 i were found to be most potent. The test compounds were found nontoxic upto the dose level of 2000 ${\mu}g$/mL. The intact compounds were then subjected for 3D-QSAR studies. 3D-QSAR study based on the principal of alignment of pharmacophoric features by Schrodinger PHASE module. The 3D-QSAR study allowed us to confirm the preferential binding mode of p-hydroxybenzohydrazide inside the active site.
Keywords
3D-QSAR; PHASE; Antimicrobial; p-Hydroxybenzohydrazide;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Tenover, F. C.; Biddle, J. W.; Lancaster, M. V. Emerg. Infect. Dis. 2001, 7, 327-32.   DOI
2 Tiwari, H. K.; Sen, M. R. BMC Infect. Dis. 2006, 6, 156.   DOI
3 Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb. Mortal. Wkly. Rep. 2002, 51, 565.
4 Smith, S. M.; Eng, R. H. Antimicrob. Agents Chemother. 1989, 33, 181-4.   DOI   ScienceOn
5 Westblom, T. U.; Abele, B. Am. J. Med. 1988, 85, 884.   DOI
6 Hansch, C.; Leo, A. American Chemical Society 1995, p 557.
7 Kubinyi.; H. Ed.; VCH: New York, 1993, p 240.
8 Bonde, C. G.; Gaikwad, N. J. bioorg. Med. Chem. 2004(12), p 2151-2561.
9 Chierakul, W.; Rajanuwong, A.; Chaowagul, W.; White, N. J. ‘Antimicrobial drugs use and therapeutics’, Trans. Royal Soc. Trop. Med. Hig 2004, 98, 678.   DOI
10 Hiramatsu, K. Am. J. Med. 1998, 104, 7S-10S.   DOI
11 Hiramatsu, K.; Hanaki, H.; Ino, T.; Tenoverm F. C. J. Antimicrob. Chemother. 1997, 40, 135-6.   DOI
12 Sieradzki, K.; Roberts, R. B.; Haber, S. W. N. Engl. J. Med. 1999, 340, 517-23.   DOI
13 Smith, T. L.; Pearson, M. L.; Wilcox, K. R. N. Engl. J. Med. 1999, 340, 493-501.   DOI
14 Barreca, M. L.; Rao, A.; S. Ferro, G. J. Chem. Inf. Model. 47 (2007) 557e562.   DOI
15 National Committee for Clinical Laboratory Standards, 6th ed., 2003, M7-A6 (ISBN 1-56238-486-4).
16 Eckert, R.; Qi, F. Antimicrob. Agents Chemother. 2006, 50, 1480-8.   DOI
17 Masunari, A.; Rezende, P.; Tavares, L. C. Abstracts of Papers, CADD & D Society in Turkey: Istanbul, 2004; p 63.
18 Ranetto, M.; Santos, M. Braz. J. Pharm. Sci., 2001; Suppl. 1, p 62.
19 Ha, K. R.; Psaltis, A. J.; Butcher, A. R. Laryngoscope 2008, 118, 535-40.   DOI
20 O’Gara, J. P. FEMS Microbiol. Lett. 2007, 270, 179-88.   DOI